Literature DB >> 22014714

Increased amount of atrial fibrosis in patients with atrial fibrillation secondary to mitral valve disease.

Guillaume S C Geuzebroek1, Shirley C M van Amersfoorth, Mark G Hoogendijk, Johannes C Kelder, Norbert M van Hemel, Jacques M T de Bakker, Ruben Coronel.   

Abstract

OBJECTIVE: Atrial fibrosis is related to atrial fibrillation but may differ in patients with mitral valve disease or lone atrial fibrillation. Therefore, we studied atrial fibrosis in patients with atrial fibrillation+mitral valve disease or with lone atrial fibrillation and compared it with controls.
METHODS: Left and right atrial appendages amputated during Maze III surgery for lone atrial fibrillation (n=85) or atrial fibrillation+mitral valve disease (n=26) were embedded in paraffin, sectioned, and stained with picrosirius red. Atria from 10 deceased patients without a cardiovascular history served as controls. A total of 1048 images (4-μm sections, 10-fold magnification, 4 images per appendage) were obtained and digitized. The percentage of fibrous tissue was calculated by quantitative morphometry.
RESULTS: Irrespective of the presence or absence of atrial fibrillation or mitral valve disease, more fibrous tissue was present in right atrial appendages than in left atrial appendages (12.7%±5.7% vs 8.2%±3.9%; P<.0001). The mean amount of fibrous tissue in the atria was significantly larger in patients with atrial fibrillation+mitral valve disease than in patients with lone AF and controls (13.6%±5.8%, 9.7%±3.2%, and 8.8%±2.4%, respectively; P<.01). No significant differences existed between patients with lone atrial fibrillation and patients without a cardiovascular history (controls).
CONCLUSIONS: Atria of patients with atrial fibrillation and mitral valve disease have more fibrosis than atria of patients with lone atrial fibrillation. However, patients with lone atrial fibrillation have an equal amount of atrial fibrosis compared with controls. These findings support the notion that fibrosis plays a more important role in the pathogenesis of atrial fibrillation secondary to mitral valve disease than in lone atrial fibrillation and potentially explains the relatively poor success of antiarrhythmic surgery in patients with mitral valve disease.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22014714     DOI: 10.1016/j.jtcvs.2011.09.022

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Fibrosis and electrophysiological characteristics of the atrial appendage in patients with atrial fibrillation and structural heart disease.

Authors:  Thomas J van Brakel; Thomas van der Krieken; Sjoerd W Westra; Jeroen A van der Laak; Joep L Smeets; Henry A van Swieten
Journal:  J Interv Card Electrophysiol       Date:  2013-09-12       Impact factor: 1.900

2.  AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2019-12-09

3.  Clinically unrecognized mitral regurgitation is prevalent in lone atrial fibrillation.

Authors:  Sanjiv Sharma; Joel Lardizabal; Mark Monterroso; Neil Bhambi; Rohan Sharma; Rasham Sandhu; Sarabjeet Singh
Journal:  World J Cardiol       Date:  2012-05-26

Review 4.  Cardiac Imaging for the Assessment of Left Atrial Mechanics Across Heart Failure Stages.

Authors:  Francesco Bandera; Anita Mollo; Matteo Frigelli; Giulia Guglielmi; Nicoletta Ventrella; Maria Concetta Pastore; Matteo Cameli; Marco Guazzi
Journal:  Front Cardiovasc Med       Date:  2022-01-13

5.  Hemodynamic parameters predict the risk of atrial fibrillation after cardiac surgery in adults.

Authors:  Rongxin Lu; Nan Ma; Zhaolei Jiang; Ju Mei
Journal:  Clin Cardiol       Date:  2017-08-29       Impact factor: 2.882

6.  Does left atrial epicardial conduction time reflect atrial fibrosis and the risk of atrial fibrillation recurrence after thoracoscopic ablation? Post hoc analysis of the AFACT trial.

Authors:  R Wesselink; J Neefs; N W E van den Berg; E R Meulendijks; M M Terpstra; M Kawasaki; F A Nariswari; F R Piersma; W J P van Boven; A H G Driessen; J R de Groot
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.